High-dose argatroban for heparin-induced thrombocytopenia in a child using a ventricular assist device

Area of Science:

• Pediatric Cardiology
• Hematology
• Cardiovascular Surgery

Background:

• Ventricular assist devices (VADs) are critical for managing pediatric heart failure.
• Heparin-induced thrombocytopenia (HIT) is a serious complication of heparin anticoagulation.
• Managing anticoagulation in VAD patients presents unique challenges.

Purpose of the Study:

• To report a case of successful argatroban treatment for heparin-induced thrombocytopenia in a pediatric VAD patient.
• To highlight the use of argatroban for VAD replacement in the context of persistent ventricular fibrillation.

Main Methods:

• A 10-year-old boy with a VAD experienced HIT.
• Treatment involved high-dose argatroban infusion to achieve therapeutic activated partial thromboplastin time.
• Bolus argatroban dosing was administered during a VAD change procedure complicated by ventricular fibrillation.

Main Results:

• High-dose argatroban infusion effectively managed HIT, achieving therapeutic anticoagulation despite elevated serum argatroban levels.
• Successful VAD replacement was performed using bolus argatroban dosing in the setting of persistent ventricular fibrillation.

Conclusions:

• Argatroban is a viable and effective alternative anticoagulant for treating HIT in pediatric VAD recipients.
• Specific argatroban dosing strategies, including bolus administration, can be crucial during complex cardiac device procedures.